Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-08-07 ms3000001758728711 来自河南省

各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭

209 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2023-04-13 14718874m55(暂无昵称) 来自辽宁省

纯SEER数据库还能投吗

85 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2023-08-17 ms2000001754372244 来自江西省

偏重的研究方向：非小细胞肺癌
经验分享：免疫组化预后预测模型可以投吗😭

113 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-09-19 ms1000001788820006 来自上海

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。

59 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-11-21 ms2000001788822130 来自上海

Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊
在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。
编辑和审稿人比较友好且专业。

10 0

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-10-25 ms1000001788822128 来自北京

editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。

50 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-10-13 ms1000001788822100 来自上海

投稿命中率:50.0
经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。
在系统中也没有看到 finalized或rejected
现在正在接受审稿人3审稿～

57 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-01-01 ms4000001668897773 来自北京

偏重的研究方向：肿瘤
经验分享：23.12.27 submit 24.1.1 仍然initial validation

94 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2024-03-21 ms4000000517261689 来自山东省

偏重的研究方向：肿瘤;免疫治疗;生信
经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…

111 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218917, encodeId=3b21221891eac, content=各位老师，一个审稿人endorsed了，但是另一个审稿人没消息，状态是We are awaiting a response from Reviewer 2 in the interactive forum.求问是什么情况啊😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=209, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48bf9338681, createdName=ms3000001758728711, createdTime=Wed Aug 07 11:37:37 CST 2024, time=2024-08-07, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2125738, encodeId=fe1f2125e3890, content=纯SEER数据库还能投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=77465191005, createdName=14718874m55(暂无昵称), createdTime=Thu Apr 13 20:11:41 CST 2023, time=2023-04-13, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2153140, encodeId=3c0a21531409e, content=偏重的研究方向：非小细胞肺癌 经验分享：免疫组化预后预测模型可以投吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=970c8803153, createdName=ms2000001754372244, createdTime=Thu Aug 17 00:28:57 CST 2023, time=2023-08-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2226687, encodeId=22e4222668e78, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我的是一篇综述，总共邀请了两位审稿人，其中一位给了修改意见。后面经历了一个多月的返修，1个月零2周的时候录用，共耗时2个多月见刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:09:00 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2238329, encodeId=724922383298f, content=Frontiers in Oncology是一本值得偏临床的医学生物研究者重视的期刊 在肿瘤学领域比较有影响力的期刊，投稿命中率为55%左右，平均审稿周期为3-4个月，涵盖了癌症研究的所有领域，包括但不限于乳腺癌、癌细胞信号转导、癌症流行病学与预防、癌症遗传学等。 编辑和审稿人比较友好且专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822130, createdTime=Thu Nov 21 23:29:45 CST 2024, time=2024-11-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233197, encodeId=bad0223319e3f, content=editorial assignment一个月了，还没分配编辑，有邮件催了，但是还是每动静，比较担心，太墨迹人了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822128, createdTime=Fri Oct 25 22:59:43 CST 2024, time=2024-10-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230668, encodeId=d99f2230668ae, content=投稿命中率:50.0 经验分享：8月份投稿，邮件总共收到2个审稿人的意见，都给了吧少意见，但是值得开心的是，没有要拒稿的意思。 在系统中也没有看到 finalized或rejected 现在正在接受审稿人3审稿～, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:43:53 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178638, encodeId=c9ba21e86387a, content=偏重的研究方向：肿瘤 经验分享：23.12.27 submit 24.1.1 仍然initial validation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=152e5448879, createdName=ms4000001668897773, createdTime=Mon Jan 01 18:38:20 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信 经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生信 经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！ 11 Apr 2023 Article accepted for publication. 07 Apr 2023 Review of Review Editor 3 finalized. 01 Apr 2023 Review of Review Editor 4 finalized. 30 Mar 2023 Review of Review Editor 1 finalized. 17 Mar 2023 Interactive review forum activated. 07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省)]

2023-04-28 ms1000001631708013 来自浙江省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;生信
经验分享：还是比较好投的，2月多投的，4月多就接受了；祝大家好运！
11 Apr 2023 Article accepted for publication.
07 Apr 2023 Review of Review Editor 3 finalized.
01 Apr 2023 Review of Review Editor 4 finalized.
30 Mar 2023 Review of Review Editor 1 finalized.
17 Mar 2023 Interactive review forum activated.
07 Feb 2023 submitted manuscript

342 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务